CheckMate-8HW: Nivolumab + Ipilimumab in MSI-H/dMMR mCRC
Microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) status is found in approximately 4% to 7% of metastatic colorectal cancer (mCRC) cases. While single-agent immunotherapy has established a new standard of care, significant unmet needs remain for many patients.
This infographic explores the latest clinical evidence for dual-agent immunotherapy and provides a comprehensive overview of the CheckMate-8HW phase 3 trial.
By reviewing this infographic, you will be able to:
- Explore recent advances in immunotherapy-based treatment options for MSI-H/dMMR metastatic colorectal cancer.
- Apply data from the CheckMate-8HW trial to guide the development of individualized treatment plans.
- Examine best practices in patient management to optimize clinical outcomes.
- Identify, recognize, and manage immune-mediated adverse events effectively.
Download the infographic to optimize first-line MSI-H/dMMR mCRC treatment and long-term survivorship strategies.
Supported by unrestricted educational funding from Bristol-Myers Squibb.
